Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/25/2005WO2005077896A1 Substituted azetidine compounds as cyclooxygenase-1-cyclooxygenase-2 inhibitors, and their preparation and use as medicaments
08/25/2005WO2005077895A1 Thioamides and salts thereof and cytokine production inhibitors containing both
08/25/2005WO2005077894A1 Modafinil compositions
08/25/2005WO2005077887A1 Novel method of synthesis and novel crystalline form of agomelatine and pharmaceutical compositions containing said form
08/25/2005WO2005077464A1 Alcohol metabolism moderating composition
08/25/2005WO2005077463A2 Ligand for a monoamine receptor or transporter for treating addiction or dependence
08/25/2005WO2005077424A2 Conjugate for destroying cancer cells
08/25/2005WO2005077423A2 Adept or gdept producing acetaldehyde
08/25/2005WO2005077420A1 Composition for oral administration of tamsulosin hydrochloride and controlled release granule formulation comprising same
08/25/2005WO2005077418A1 Combination of renin inhibitor and diuretics
08/25/2005WO2005077416A2 Lipid rafts and clostridial toxins
08/25/2005WO2005077413A1 Ctgf as target for the therapy of diabetic nephropathy
08/25/2005WO2005077405A1 Compositions and methods for the treatment of cancer by systemic elevation of lactate and consequent depletion of arginine
08/25/2005WO2005077394A1 Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
08/25/2005WO2005077386A1 Composition and method for use in cartilage affecting conditions
08/25/2005WO2005077385A2 Methods for treating resistant or refractory tumors
08/25/2005WO2005077384A1 Lipase activity inhibitor containing high-molecular weight polyphenol fraction, tea extract and process for producing the same
08/25/2005WO2005077383A1 The use of o-atp for the treatment of diseases involving angiogenesis
08/25/2005WO2005077382A1 Prion growth inhibitor
08/25/2005WO2005077381A1 Use of ginsenoside re for preparation of medicaments for treating dysmnesia
08/25/2005WO2005077380A1 External preparation for treating painful skin wound
08/25/2005WO2005077379A1 Remedy for external use for skin and mucosal injuries caused by viral infection
08/25/2005WO2005077378A1 Method of preventing, medicating and/or treating hypocalcaemia of domestic mammal
08/25/2005WO2005077377A1 Compositions that include a triterpene and a carrier
08/25/2005WO2005077376A1 A stable parental formulation of levomepromazine and a method for stabilizing said formulation
08/25/2005WO2005077375A1 Pde5 inhibitors for the treatment of cancer
08/25/2005WO2005077374A1 Formulations of phosphodiesterase 5 inhibitors and methods of use
08/25/2005WO2005077373A2 Treatment of gastro-esophageal reflux disease (gerd)
08/25/2005WO2005077372A1 Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma
08/25/2005WO2005077371A1 Use of levocetirizine for the preparation of a drug
08/25/2005WO2005077370A1 Aqueous solution preparation containing camptothecins
08/25/2005WO2005077369A1 Piperidine derivatives useful as ccr3 antagonists
08/25/2005WO2005077368A2 Treatment of gastro-esophageal reflux disease (gerd)
08/25/2005WO2005077367A1 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-2s-phenyl-piperidin-3s-yl)-amine for the treatment of social phobia
08/25/2005WO2005077366A1 Use of non-peptidic nk1 receptor antagonists for the production of apoptosis in tumour cells
08/25/2005WO2005077365A2 Novel uses for proton pump inhibitors
08/25/2005WO2005077364A1 Transdermal solifenacin preparation and method of improving transdermal permeability thereof
08/25/2005WO2005077363A1 Heterocyclic gaba-a subtype selective receptor modulators
08/25/2005WO2005077362A1 Method of treating and diagnosing sleep disordered breathing using zonisamide and means for carrying out the method
08/25/2005WO2005077361A1 Novel, sustained-action beta-2-agonists and their use as medicaments
08/25/2005WO2005077360A2 Topical treatment of otitis externa with antifungals or antibacterials
08/25/2005WO2005077359A1 Stabilized pharmaceutical composition containing indoline compound
08/25/2005WO2005077358A1 Drug for osteoporosis comprising kampferol as the active ingredient
08/25/2005WO2005077357A1 Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
08/25/2005WO2005077356A2 Glycine and/or for use in cartilage affecting conditions
08/25/2005WO2005077355A1 Pharmaceutical compositions for the prevention or treatment of diseases accompanied by esophageal dyskinesia
08/25/2005WO2005077354A1 Compounds having antitumor activity
08/25/2005WO2005077352A1 Use of 2,5-dihydroxybenzenesulphonic acid in the production of medicaments for the treatment of angiodependent diseases such as cancer and psoriasis
08/25/2005WO2005077351A1 Quinone remedies for lung diseases
08/25/2005WO2005077350A1 Method for enhancing the bioavailability of ospemifene
08/25/2005WO2005077349A1 HUMAN β-DEFENSIN PRODUCTION ACCELERATOR
08/25/2005WO2005077348A1 Treating or preventing diabetes with cannabidiol
08/25/2005WO2005077347A1 Use of endothelin antagonists to prevent restenosis
08/25/2005WO2005077346A1 Controlled release formulations
08/25/2005WO2005077345A1 Compounds for the treatment of gastro-esophageal reflux disease
08/25/2005WO2005077343A2 Novel drugs and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases
08/25/2005WO2005077341A1 Orally disintegrating pharmaceutical compositions of ondansetron
08/25/2005WO2005077340A1 Multiparticulate o-desmethylvenlafaxine salts and uses thereof
08/25/2005WO2005077339A1 Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister
08/25/2005WO2005077337A2 Dispersions prepared by use of self-stabilizing agents
08/25/2005WO2005077332A2 Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof
08/25/2005WO2005077331A1 Chronotherapeutic compositions and methods of their use
08/25/2005WO2005077269A1 Substituted porphyrins
08/25/2005WO2005077176A1 Anthocyanin compounds and methods of use thereof
08/25/2005WO2005077168A1 Method and compositions for treatment of painful disorders
08/25/2005WO2005077126A2 Use of ppargamma specific inhibitors as anti-cancer therapeutics
08/25/2005WO2005077122A2 Compounds and compositions as lxr modulators
08/25/2005WO2005077111A2 Method and preparation for reducing skin hyperpigmentation
08/25/2005WO2005077091A2 Nicotinamide riboside kinase compositions and methods for using the same
08/25/2005WO2005077082A2 INHIBITING CAV3 ISOFORMS AND THE δ25B SPLICE VARIENTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
08/25/2005WO2005077056A2 Methods and compositions for the treatment of inflammation
08/25/2005WO2005077019A2 Protease inhibitors for treatment of wrinkles
08/25/2005WO2005077007A2 Methods of diagnosing and treating pre-eclampsia or eclampsia
08/25/2005WO2005077006A2 Methods and compositions for detecting and treating retinal diseases
08/25/2005WO2005076987A2 Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
08/25/2005WO2005076899A2 Oral androgen therapy using modulators of testosterone bioavailablity
08/25/2005WO2005076888A2 Anti-cancer therapies
08/25/2005WO2005076854A2 Pyrimidinone compounds useful as kinase inhibitors
08/25/2005WO2005076829A2 Stable loratadine spill resistant formulation
08/25/2005WO2005076731A2 High salt compositions, methods of producing same and methods of use thereof
08/25/2005WO2005076695A2 Methods of modulating neurotrophin-mediated activity
08/25/2005WO2005063767A3 Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
08/25/2005WO2005063764A3 Fused pyrrolocarbazoles and methods for the preparation thereof
08/25/2005WO2005063225A8 Compositions and methods for treating hepatitis c virus (hcv) infection
08/25/2005WO2005062824A3 Anti-hypercholesterolemic compounds
08/25/2005WO2005058911A3 Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma
08/25/2005WO2005058310A3 Use of stating for the treatment of metabolic syndrome
08/25/2005WO2005055947A3 Enlargement of mucocutaneous or cutaneous organs and sites with topical compositions
08/25/2005WO2005055945A3 Mucoadhesive drug delivery devices and methods of making and using thereof
08/25/2005WO2005053739A3 Combination therapy
08/25/2005WO2005053682A3 Use of beta-lapachone for protecting against radiation injury
08/25/2005WO2005053616A3 Antimicrobial composition
08/25/2005WO2005051369A8 Reversing, postponing or preventing the occurrence of gtn tolerance and/or generation of reactive oxygen species from mitochondria
08/25/2005WO2005051346A3 Compositions comprising organic compounds
08/25/2005WO2005049827B1 Ppmp as a ceramide catabolism inhibitor for cancer treatment
08/25/2005WO2005047303A3 NOVEL 17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
08/25/2005WO2005046727A3 Ibuprofen-containing soft gelatin capsules
08/25/2005WO2005044251A3 Methods of lowering lipid levels in a mammal
08/25/2005WO2005044182A3 Compositions of botanical extracts for cancer therapy
08/25/2005WO2005042534A3 A2b adenosine receptor antagonists
1 ... 4565 4566 4567 4568 4569 4570 4571 4572 4573 4574 4575 4576 4577 4578 4579 4580 4581 4582 4583 4584 4585 ... 7860